药物发现
损耗
药物开发
过程(计算)
投资(军事)
制药工业
药品
候选药物
钥匙(锁)
生化工程
风险分析(工程)
计算机科学
药理学
业务
医学
生物
工程类
生物信息学
政治学
法学
政治
操作系统
牙科
计算机安全
作者
Peter Ballard,Patrick Brassil,Khanh Bui,Hugues Dolgos,Carl Petersson,Anders Tunek,Peter J. H. Webborn
标识
DOI:10.3109/03602532.2012.691099
摘要
The high rate of attrition during drug development and its associated high research and development (R&D) cost have put pressure on pharmaceutical companies to ensure that candidate drugs going to clinical testing have the appropriate quality such that the biological hypothesis could be evaluated. To help achieve this ambition, drug metabolism and pharmacokinetic (DMPK) science and increasing investment have been deployed earlier in the R&D process. To gain maximum return on investment, it is essential that DMPK concepts are both appropriately integrated into the compound design process and that compound selection is focused on accurate prediction of likely outcomes in patients. This article describes key principles that underpin the contribution of DMPK science for small-molecule research based on 15 years of discovery support in a major pharmaceutical company. It does not aim to describe the breadth and depth of DMPK science, but more the practical application for decision making in real-world situations.
科研通智能强力驱动
Strongly Powered by AbleSci AI